3.37 USD
▲-0.08+0.30%
盘后 3.46 +2.93%
2026-08-03
市值
$29.13M
市盈率
—
EPS
-9.66
股息率
—
52 周区间
2.60 – 14.68
成交量
143.95K
Beta
1.54
目标价
—
52W 低 2.6052W 高 14.68
价格走势
公司简介
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore Co...